DP
ZVRA icon

Diadema Partners’s Zevra Therapeutics ZVRA Stock Holding History

Diadema Partners’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-42,081
Closed -$351K – 157
2024
Q4 		$351K Buy
+42,081
New +$359K 0.15% 79

Other funds holding ZVRA

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Diadema Partners's ZVRA Position: Q1 2025 in Review

Diadema Partners sold out of Zevra Therapeutics (ZVRA) in Q1 2025, closing a stake of 42,081 shares — an estimated $351K sold.

Diadema Partners first reported a position in ZVRA in Q4 2024 and held it in 1 quarter. The position peaked at $351K in Q4 2024. 110 funds tracked by Wall St. Rank hold ZVRA as of Q1 2025.

  • Diadema Partners reported no remaining Zevra Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Diadema Partners sold 42,081 Zevra Therapeutics shares in Q1 2025, an estimated $351K.
  • Diadema Partners first reported a position in Zevra Therapeutics in Q4 2024 and held it in 1 quarter.
  • Diadema Partners's Zevra Therapeutics position peaked at $351K in Q4 2024.
  • 110 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2025.

Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.